BioSpace News Archive

Business

Gilead and Lyndra Team Up to Develop Long-Acting HIV Therapies

Gilead is paying Lyndra $15 million upfront to develop a formulation for HIV that can be taken once a week, as opposed to every day.

July 9, 2019
·
2 min read
·
Mark Terry
ADC Therapeutics Rakes in $303 Million with Addition to its Series E

ADC Therapeutics, headquartered in Lausanne, Switzerland, closed on a $103 million Series E financing expansion, bringing the total proceeds to $303 million.

July 9, 2019
·
2 min read
·
Mark Terry
BioCapital

PhRMA-backed Study Shows Hospitals Significantly Hike Drug Prices

The study data shows that the amount hospitals receive after negotiations with commercial payers is, on average, almost twice what they paid to acquire the medicine.

July 9, 2019
·
2 min read
·
Alex Keown
Business

J&J’s Janssen Doubles Down on Bioinformatics with Celsius Therapeutics Partnership

Under the terms of the agreement, Celsius will use its single-cell genomics and machine learning platform to attempt to identify predictive biomarkers from Janssen’s VEGA Phase IIa clinical trial.

July 9, 2019
·
2 min read
·
Mark Terry
Biotech Bay

Revolution Medicines Snags $100 Million to Target RAS Pathway

Bay Area-based Revolution Medicines Inc. secured $100 million in Series C financing that will be used to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.

July 9, 2019
·
2 min read
·
Alex Keown
Business

Commuting Can Become a Waiting Game in These Biotech Hubs

A recent report from Business Insider ranked the 50 worst places in the United States for traffic commutes and the main biotech hubs were all included.

July 9, 2019
·
4 min read
·
Alex Keown
How the Pharmaceutical Industry is Looking to Treat Low Sex Drive

It should be noted that if someone just happens to have a low sex drive and is completely fine with that then it’s not a medical problem in any form. However, if having a low sex drive is negatively impacting a person’s life and well-being, then they may have hypoactive sexual desire disorder.

July 9, 2019
·
3 min read
·
Sasha Mortimer
Immunotherapy could work against bowel cancers resistant to important targeted treatment

Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.

July 9, 2019
·
7 min read
Business

Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand

Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.

July 9, 2019
·
4 min read
IBA signs contract to install proton therapy center in Kansas, USA

Construction to host IBA’s Proteus®ONE system expected to start later this year

July 9, 2019
·
4 min read